uniQure N.V. (NASDAQ:QURE) has been downgraded from Buy to Hold in a statement by Jefferies & Co earlier today.
- Updated: November 27, 2016
Boasting a price of $6.94, uniQure N.V. (NASDAQ:QURE) traded 2.39% higher on the day. With the last stock price close down -19.81% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. uniQure N.V. has recorded a 50-day average of $7.17 and a two hundred day average of $8.54. Volume of trade was down over the average, with 58,487 shares of QURE changing hands under the typical 226,691
Jefferies & Co has downgraded uniQure N.V. (NASDAQ:QURE) from Buy to Hold in a statement released on 11/22/2016.
On 11/17/2016, Zacks Investment Research released a statement for uniQure N.V. (NASDAQ:QURE) bumped up the target price from $0.00 to $8.00 that suggested an upside of 0.14%.
With a total market value of $0, uniQure N.V. has with a one year low of $6.41 and a one year high of $22.00 .
Brief Synopsis About uniQure N.V. (NASDAQ:QURE)
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.